Step-Ups in Recent Biotech IPOs
This article was originally published in Start Up
Executive Summary
As biotech IPOs continue to enjoy record-high valuations, we wondered if rates of return on these deals varied with different biotech business models-specifically, platform technology-based companies pursuing a service relationship with pharmaceuticals companies as opposed to those actually pursuing clinical development of drugs themselves.